双重pH/温度敏感的纤维素纳米晶体,具有定制的双触发结构适应性,用于控制释放的口服片
Yi Chen1, Bowen Jia1, Junjie Zhou1
1State Key Laboratory of Bio-based Fiber Materials, Zhejiang Sci-Tech University, Xiasha Higher Education Park Avenue 2 No.928, Hangzhou, 310018, China.
International journal of biological macromolecules
|February 18, 2026
概括
研究人员开发了双pH/温度响应的纤维素纳米晶体,用于智能口服药物输送. 这些工程材料能够快速,可控地释放药物,为向的胃癌治疗显示出希望.
科学领域:
- 材料科学 材料科学 材料科学
- 生物材料工程 生物材料工程
- 制药科学 制药科学
背景情况:
- 设计具有响应释放机制的口服固体制剂对于胃肠道疾病的精确治疗疗效至关重要.
- 纤维素纳米晶 (CNCs) 提供了一个多功能平台,用于药物输送,因为它们的生物相容性和可调节性质.
研究的目的:
- 为了设计一个双pH/温度响应的纤维素纳米晶体 (CNCs-D-N),用于控制药物释放.
- 制造和表征刺激敏感片 (CNC@DNWT) 用于口服药物输送.
- 评估药物释放动力学和针对性胃癌治疗的潜力.
主要方法:
- 在碳氧化纤维素纳米晶体上对刺激敏感的共聚合物进行移植,以创建CNCs-D-N.
- 湿装四环素化物进入CNCs-D-N以制造CNC@DNWT片.
- 在模拟的胃条件下评估机械特性,药物载荷能力和释放动力学.
主要成果:
- CNCs-D-N表现出pH依赖和热诱导的结构适应性,用于受控的分子延伸和收缩.
- CNC@DNWT平板显示出卓越的机械稳定性,高药物负载 (99%) 和超快释放启动 (7秒).
- 在模拟的胃条件下 (pH 3,37°C) 达到99%的累积药物释放,突出了协同的双刺激效应.
结论:
- 开发的CNCs-D-N为智能纤维素基口服配方提供了一种机械战略.
- 这种方法可以通过双重pH/温度反应来精确控制药物释放动力学.
- 显示了针对性胃癌治疗和其他胃肠道疾病治疗的显著潜力.
更多相关视频
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
36
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
36
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
26
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
26
01:11Oral Drug Delivery Systems: Delayed-Release Systems
41
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
41
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
26
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
26
01:23Modified-Release Drug Delivery Systems: Classification
41
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
41
01:26Oral Drug Delivery Systems: Continuous-Release Systems
40
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
40